SS-31 Benefits and Side Effects: A Research Guide

SS-31 (Szeto-Schiller peptide 31, also known as Elamipretide, Bendavia, or MTP-131) is a synthetic tetrapeptide — D-Arg-2',6'-dimethyl-Tyr-Lys-Phe-NH₂ — developed by Hazel Szeto and Peter Schiller. It is the most clinically advanced of the mitochondria-targeted peptides, with multiple Phase II and Phase III trials completed in mitochondrial myopathy, Barth syndrome, age-related macular degeneration, and heart failure.

This guide summarises what the published research literature reports about SS-31's mechanism, outcomes investigated, and its side-effect profile. It is written for laboratory researchers and is not medical advice.

Mechanism of Action

SS-31 is mechanistically distinct from most peptide therapeutics:

• Selective cardiolipin binding. SS-31 concentrates in the inner mitochondrial membrane (1000-fold over cytoplasm in published assays) and binds cardiolipin — a phospholipid unique to that membrane.
• Electron-transport-chain stabilisation. By stabilising the cardiolipin-cytochrome c interaction, SS-31 preserves supercomplex assembly, restores electron-transport efficiency, and reduces electron leak and reactive oxygen species (ROS) generation.
• No receptor-mediated mechanism. Unlike most peptides, SS-31 has no known cell-surface receptor — its action is biophysical, at the inner mitochondrial membrane.
• Restoration of ATP synthesis. Downstream of supercomplex stabilisation, SS-31 restores ATP production in dysfunctional mitochondria without affecting healthy mitochondrial function.

Reported Benefits in the Research Literature

Mitochondrial Myopathies SS-31 has been studied in primary mitochondrial myopathy patients (the MMPOWER trials), with reported improvements in six-minute-walk distance and patient-reported fatigue scores.

Heart Failure Multiple animal models and the EMBRACE-STEMI trial investigated SS-31 in ischemia-reperfusion injury and chronic heart failure. Animal data are consistently positive (preserved ejection fraction, reduced infarct size); human trials have shown more variable signals depending on endpoint and population.

Age-Related Macular Degeneration (ReCLAIM trials) SS-31 has been investigated in dry AMD and geographic atrophy, with reported improvements in low-luminance visual acuity and ellipsoid-zone preservation in subsets of patients.

Barth Syndrome A rare X-linked disorder of cardiolipin metabolism — SS-31 received orphan designation and produced measurable improvements in cardiac and skeletal-muscle endpoints in this population.

Aging Research A growing body of preclinical work reports that SS-31 reverses age-related mitochondrial dysfunction in skeletal muscle, kidney, and brain tissue — restoring ATP production, reducing ROS, and improving organ function in aged rodents. This is the basis of its growing prominence in the longevity research literature.

Renal Ischemia SS-31 has been studied in acute kidney injury models with consistent renoprotective signals attributed to preserved mitochondrial function in proximal tubular cells.

Side Effects and Safety Signals

Across the substantial clinical trial dataset, SS-31 has been well tolerated, with a side-effect profile dominated by local injection-site reactions:

• Injection-site reactions. The most common reported adverse event — erythema, pruritus, and induration at subcutaneous injection sites. Generally mild-to-moderate and transient.
• No HPA-axis, prolactin, thyroid, or sex-hormone disturbance in the published cohorts.
• No reported hepatic, renal, or haematological toxicity at investigated doses.
• Cardiac safety reassuring — relevant given heart-failure trial population.

The published Phase II/III safety dataset for Elamipretide is one of the most substantial for any mitochondria-targeted compound, providing strong reassurance on the general safety profile.

SS-31 vs. Related Compounds

• SS-31 vs. [MOTS-c](/research/hubs/mots-c). Both mitochondrial-research compounds but mechanistically different — SS-31 is a biophysical inner-membrane stabiliser; MOTS-c is a signalling peptide acting through AMPK.
• SS-31 vs. [NAD](/catalog/nad-plus)⁺ precursors (NMN, NR). NAD⁺ precursors support sirtuin-mediated mitochondrial biogenesis; SS-31 preserves existing mitochondrial function. Complementary rather than competing in research designs.
• SS-31 vs. CoQ10 / MitoQ. Both target mitochondrial ROS, but via different mechanisms — antioxidants vs. supercomplex stabilisation. SS-31 does not act primarily as an antioxidant; its ROS reduction is downstream of restored electron-transport efficiency.
• SS-31 vs. urolithin A. Different mechanism — urolithin A promotes mitophagy (turnover); SS-31 preserves function of existing mitochondria.

Research Handling Considerations

SS-31 is supplied as a lyophilised powder, reconstituted with bacteriostatic water for research use. Subcutaneous administration is standard in the published literature, with most protocols using daily dosing over multi-week intervals. The peptide is highly water-soluble and stable in solution under standard refrigerated conditions; always confirm against the batch certificate of analysis.

Bottom Line

SS-31 / Elamipretide is the most clinically advanced and mechanistically distinctive mitochondria-targeted peptide in the published research literature. Its biophysical action on cardiolipin and the inner mitochondrial membrane sets it apart from receptor-mediated peptide therapeutics, and the cumulative Phase II/III safety dataset is substantial. For investigators building models of mitochondrial dysfunction, ischemia-reperfusion injury, or age-related organ decline, SS-31 is a foundational reference compound and a natural pairing with MOTS-c and NAD⁺ precursors in mitochondrial-research designs.